SEC Filing Summary: Aastrom Biosciences, Inc. (Form 10-Q)
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Aastrom Biosciences, Inc. (Note: The input metadata referenced "Vericel Corp," but the filing text explicitly identifies the registrant as Aastrom Biosciences, Inc.). The report covers the quarterly period ended December 31, 1997, and the six-month period ended on the same date. The Company is in the development stage, focusing on research and product development for the ex vivo production of human stem cells and hematopoietic tissues, specifically the Aastrom Cell Production System (CPS). It has not yet generated revenue from product sales.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 1997 | Six Months Ended Dec 31, 1996 | Balance Sheet (Dec 31, 1997) |
|---|---|---|---|
| Total Revenues | $65,000 | $253,000 | - |
| Net Loss | $(8,033,000) | $(6,162,000) | - |
| Net Loss Per Share (Diluted) | $(0.87) | $(0.61) | - |
| Research & Development Expenses | $7,031,000 | $5,710,000 | - |
| Cash and Cash Equivalents | - | - | $1,270,000 |
| Short-term Investments | - | - | $18,511,000 |
| Total Current Assets | - | - | $20,078,000 |
| Total Current Liabilities | - | - | $2,068,000 |
| Accumulated Deficit | - | - | $(49,394,000) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues for the six months ended December 31, 1997, decreased to $65,000 from $253,000 in the prior year period. This decrease reflects the completion of a research collaboration in September 1996, partially offset by an increase in grant revenues.
- Expense Increase: Total costs and expenses rose to $8,527,000 for the six months ended December 31, 1997, compared to $6,601,000 in 1996. Research and development expenses increased to $7,031,000 (from $5,710,000) due to increased development activities for the Aastrom CPS. General and administrative expenses also increased to $1,496,000 (from $891,000).
- Widening Loss: The net loss for the six-month period increased to $8,033,000 from $6,162,000 in the prior year. The net loss per common share increased to $(0.87) from $(0.61).
- Capital Raise: In December 1997, the Company completed a directed placement of 2,200,000 shares of 5.5% Convertible Preferred Stock, generating net proceeds of approximately $9,930,000. This significantly bolstered liquidity.
Guidance, Outlook, and Risks
- Liquidity and Capital Resources: The Company holds approximately $19.8 million in combined cash, cash equivalents, and short-term investments as of December 31, 1997. Management does not expect to generate positive cash flows from operations for at least the next several years. Future funding will likely come from collaborative arrangements, grants, or public/private financing.
- Outlook: The Company expects operating expenses and net losses to continue to increase as it expands research, clinical, and regulatory activities. It anticipates no net income for the foreseeable future.
- Risks and Contingencies:
- Regulatory Approval: Commercialization depends on FDA approval and foreign regulatory approvals, which are not guaranteed. The Company is currently conducting pre-pivotal clinical trials.
- Development Risks: There is no assurance that the Aastrom CPS or other candidates will successfully complete development or gain market acceptance.
- Supply Chain: The Company relies on third parties for manufacturing key components (cytokines, serum, media). Interruptions in supply could materially adversely affect operations.
- Strategic Alliance: The distribution agreement with Cobe BCT, Inc. allows Cobe to terminate the agreement with 12 months' notice if commercialization by December 31, 1998, is deemed unlikely.
- Unusual Items: The computation of net loss per common share for 1997 includes a one-time charge of $3,439,000 related to the sale of Preferred Stock and an adjustment for dividends paid on Preferred Stock. These items affect per-share calculations but are not included in the net loss figure itself.
Investor Verification Checklist
- Verify the status and results of the pre-pivotal clinical trials for the Aastrom Cell Production System (CPS).
- Confirm the terms and stability of the distribution agreement with Cobe BCT, Inc., specifically regarding the December 31, 1998, commercialization milestone.
- Assess the Company's ability to secure additional funding given the expectation of continued operating losses and the lack of product revenue.
- Review the supply chain dependencies for key cytokines and components to evaluate potential manufacturing risks.
- Monitor the conversion terms of the 5.5% Convertible Preferred Stock issued in December 1997 and its potential dilution impact on common shareholders.